Measured by its ability to neutralize CXCL9/MIG-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with mouse CXCR3. The Neutralization Dose (ND50) is typically 3-12 µg/mL in the presence of 1 μg/mL Recombinant Human CXCL9/MIG.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Chemotaxis Induced by CXCL9/MIG and Neutralization by Human CXCL9/ MIG Antibody.
Recombinant Human CXCL9/ MIG (Catalog # 392‑MG) chemoattracts the BaF3 mouse pro‑B cell line transfected with mouse CXCR3 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CXCL9/ MIG (1 μg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human CXCL9/MIG Antigen Affinity-purified Polyclonal Antibody (Catalog # AF392). The ND50 is typically 3‑12 µg/mL.
CXCL9/MIG in THP‑1 Human Cell Line. CXCL9/MIG was detected in immersion fixed THP‑1 human acute monocytic leukemia cell line stimulated with IFN-gamma using Goat Anti-Human CXCL9/MIG Antigen Affinity-purified Polyclonal Antibody (Catalog # AF392) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Cells on Coverslips.
Preparation and Storage
Reconstitute at 0.2 mg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
CXCL9, a member of the alpha subfamily of chemokines that lack the ELR domain, was initially identified as a lymphokine-activated gene in mouse macrophages. Human CXCL9was subsequently cloned using mouse MIG cDNA as a probe. The CXCL9 gene is induced in macrophages and in primary glial cells of the central nervous system specifically in response to IFN-gamma. CXCL9 has been shown to be a chemoattractant for activated T-lymphocytes and TIL but not for neutrophils or monocytes. The human CXCL9 cDNA encodes a 125 amino acid residue precursor protein with a 22 amino acid residue signal peptide that is cleaved to yield a 103 amino acid residue mature protein. CXCL9 has an extended carboxy-terminus containing greater than 50% basic amino acid residues and is larger than most other chemokines. The carboxy-terminal residues of CXCL9 are prone to proteolytic cleavage resulting in size heterogeneity of natural and recombinant CXCL9. CXCL9 with large carboxy-terminal deletions have been shown to have diminished activity in the calcium flux assay. A chemokine receptor (CXCR3) specific for CXCL9 and IP-10 has been cloned and shown to be highly expressed in IL-2-activated T-lymphocytes. The E. coli-expressed CXCL9 preparations produced at R&D Systems have been shown to contain greater than 80% full length CXCL9.
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.